Check for updates

OPEN ACCESS

EDITED BY Antonio Colantuoni, University of Naples Federico II, Italy

REVIEWED BY

Francesca Ghirardini, ULSS 1 Belluno, Italy Dominga Lapi, University of Naples Federico II, Italy

*CORRESPONDENCE Yan Yue, ⊠ yueyan_1994@163.com Dezhi Mu, ⊠ mudz@scu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 03 February 2024 ACCEPTED 15 May 2024 PUBLISHED 03 June 2024

CITATION

Deng B, Lei Y, Zhou R, Ruan T, Lu W, Ying J, Yue Y and Mu D (2024), Effect of blueberry intervention on endothelial function: a systematic review and meta-analysis. *Front. Physiol.* 15:1368892. doi: 10.3389/fphys.2024.1368892

COPYRIGHT

© 2024 Deng, Lei, Zhou, Ruan, Lu, Ying, Yue and Mu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effect of blueberry intervention on endothelial function: a systematic review and meta-analysis

Bixin Deng^{1†}, Yupeng Lei^{1†}, Ruixi Zhou^{1,2}, Tiechao Ruan¹, Wenting Lu³, Junjie Ying², Yan Yue^{1,2}* and Dezhi Mu^{1,2}*

¹Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China, ²Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, China, ³Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China

Introduction: Endothelial dysfunction indicates blood vessel injury and is a risk factor for cardiovascular diseases. Blueberry has been approved for its benefits on human health, especially on cardiovascular function. However, its effect on endothelial function remains unclear. We conducted a systematic review and meta-analysis to explore the impact of blueberries on endothelial function in adults.

Methods: We searched PubMed, Web of Science, Embase, and the Cochrane Library, 16 studies were included in the systematic review, and 11 were used for the meta-analysis. Data associated with endothelial function were extracted and pooled as mean differences (MD) with 95% confidence intervals (CI).

Results: Blueberry consumption significantly improved flow-mediated dilation (FMD) by 1.50% (95% CI: 0.81, 2.20; $I^2 = 87\%$) and reactive hyperemia index (RHI) by 0.26 (95% CI: 0.09, 0.42; $I^2 = 72\%$). A significant decrease in diastolic blood pressure (DBP) was also observed (MD: -2.20 mm Hg; 95% CI: -4.13, -0.27; $I^2 = 11\%$). Subgroup analysis indicated a significant decrease in blood pressure (Systolic blood pressure [SBP]: -3.92 mmHg; 95% CI: -6.88, -0.97; $I^2 = 20\%$ and DBP: -2.20 mmHg; 95% CI: -4.13, -0.27; $I^2 = 11\%$) in the smoking population. However, SBP levels (MD: -1.43 mm Hg; 95% CI: -3.11, 0.26; $I^2 = 20\%$) and lipid status (high-density lipoprotein cholesterol [HDL-C]: 0.06; 95% CI: -0.04, 0.16; $I^2 = 77\%$; low-density lipoprotein cholesterol [LDL-C]: 0.05; 95% CI: -0.14, 0.24; $I^2 = 0\%$) did not significantly improve.

Conclusion: Blueberry intervention improved endothelial function and DBP. Subgroup analysis revealed a notable improvement in blood pressure among the smoking population. However, no significant effects were observed on SBP, HDL-C, and LDL-C levels. Future research should delve into the mechanisms of endothelial improvement and verify blood pressure reduction in specific subpopulations through large-scale trials.

Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPERO/, Identifier CRD42023491277.

KEYWORDS

endothelial dysfunction, blueberry, blood pressure, review, meta-analysis

1 Introduction

Endothelial cells are located on the inner surfaces of blood and lymphatic vessels; they possess sensory and effector regulatory capabilities and metabolic and synthetic functions (Parenti et al., 2017). Studies have shown that endothelial cells are crucial in various physiological and metabolic functions, including immune and inflammatory processes in the cardiovascular network, thrombosis and thrombolysis control, platelets or leukocytes interactions with the vascular wall, angiogenesis, and vascular tone regulation (Durand and Gutterman, 2013; Rajendran et al., 2013).

Consequently, endothelial dysfunction predicts the progression of anatomically significant vascular diseases and is strongly associated with the development of various cardiovascular diseases (Virdis and Taddei, 2011; Silva et al., 2012). Endothelial dysfunction is a hallmark of hypertension (Virdis and Taddei, 2011) and is the earliest observable change in atherosclerosis (Rajendran et al., 2013). In addition, impaired endothelial function has been demonstrated in conditions such as peripheral arterial occlusive disease, coronary artery disease, and heart failure (Virmani et al., 2002).

Endothelial dysfunction is primarily due to an imbalance in the production and bioavailability of vasodilators and vasoconstrictors (Rajendran et al., 2013). This imbalance predominantly results from reduced vascular bioavailability of nitric oxide (NO), ultimately leading to impaired vascular endothelium-dependent relaxation function (Kinugawa et al., 2003). Diverse pathophysiological events can contribute to endothelial dysfunction, including factors such as hypercholesterolemia (oxidatively modified lipoproteins), metabolic syndrome [reactive oxygen species (ROS), adipokines], hypertension (angiotensin-II, ROS), aging, proinflammatory cytokines [interleukin-1 (il-1), tumor necrosis factor- α], hemodynamic forces, and oxidative stress (Bove et al., 2017).

Flow-mediated vasodilation (FMD) is an endotheliumdependent process that reflects the ability of blood vessels to respond to physical and chemical stimuli in the lumen. This capacity enables the vessel to self-regulate tone and adjust blood flow and distribution in response to local environmental changes (Corretti et al., 2002). The reactive hyperemia index (RHI) was automatically derived in an operator-independent manner, reflecting NO bioavailability and correlating with coronary endothelial vasodilatory function measurements and brachial artery FMD (Axtell et al., 2010). Lower RHI scores indicate endothelial dysfunction.

Endothelial dysfunction is reversible; therefore, approaches capable of reversing it are appealing strategies for treating cardiovascular diseases (Celermajer, 1997). Polyphenol-rich foods confer cardiovascular health benefits, as evidenced by randomized controlled human intervention trials. They positively impact various well-characterized cardiovascular disease risk factors, including endothelial dysfunction, hypertension, lipid metabolism, and platelet activity (Del Rio et al., 2013).

Blueberries are particularly rich in (poly)phenolics, such as anthocyanins and phenolic acids, and there is growing evidence of their cardiovascular protective effects (Cutler et al., 2017). Furthermore, studies have shown that blueberry consumption reduces oxidative stress (Woolf et al., 2023b) and cardiovascular events (Wood et al., 2023); however, another study suggested that blueberry use does not improve endothelial function (Del Bo et al., 2013). Furthermore, the effects of blueberries on endothelial function have yet to be systematically reviewed. Therefore, this study aimed to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of blueberries on endothelial function in adults.

2 Materials and methods

2.1 Registration

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This metaanalysis and systematic review were prospectively registered in PROSPERO (CRD42023491277).

2.2 Information sources and search strategies

We performed systematic literature searches of PubMed, Cochrane, Embase, and the Web of Science electronic databases. The search was conducted until December 2023. The structured search strategy was designed using the following medical subject headings (MeSH) search terms: "Blueberry Plants," or text words "Plant, Blueberry," "Blueberry Plant," "Vaccinium virgatum," "Vaccinium ashei," "Vaccinium uliginosum," "Vaccinium angustifolium," "Blueberry," "Vaccinium corymbosum," and text words "Flow-mediated dilatation," "Flow-mediated dilation," "Venous occlusion plethysmography," "Peripheral arterial tonometry," "Nitric oxide," "Nitrite," "Nitrate," "Endothelial function," "Endothelial dysfunction." This search strategy was adapted for the other electronic databases used. In addition, we identified eligible studies by searching the reference lists of the included studies.

2.3 Eligibility criteria


The eligibility criteria included studies reporting indicators of endothelial function in individuals who consumed blueberries. Publication dates were unrestricted, and narrative reviews, animal research, case reports, comments, and editorials were excluded.

2.4 Study selection process

One investigator performed the database search and screened for duplicates. After excluding duplicates, two investigators [Bixin Deng (BD) and Yupeng Lei (YL)] screened the titles and abstracts of all records and evaluated the full text of the eligible articles.

2.5 Data collection and processing

Information on study design/methodology, author name, publication year, place of study, sample size, intervention details (types and doses of blueberries), and indices associated with



endothelial function [FMD, RHI, blood pressure, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)] were extracted from the included studies. Each study's mean and standard deviation (SD) data was obtained. For s tudies lacking SD information, the following equation was used: SD change = square root [(SDbaseline2 + SDfinal2)-(2 × R × SDbaseline × SDfinal)], where a correlation coefficient (R) of 0.5, within the predictable range of 0–1, was used as a conservative measure.

2.6 Study risk of bias assessment

Two reviewers (BD and TR) independently evaluated the risk of bias in all selected studies using the revised Cochrane risk of bias tool for individually randomized parallel-group trials (RoB2.0). Assessing the risk of bias involved each study's six domains, categorized into three grades: low, unclear, and high risk of bias. The overall risk of bias was determined using a combination of the other five domains.

2.7 Statistical analysis

Meta-analysis of eligible studies, including FMD and RHI, was conducted using the Stata 12 (StataCorp, College Station, TX, United States) and Review Manager software (RevMan 5.3, Cochrane Collaboration, Oxford, United Kingdom). The mean and SD values from the included studies were pooled using the RevMan 5.3. Statistical heterogeneity among the included studies was assessed using the I² value and Q test. The degree of heterogeneity was categorized based on the I² value, with classifications including low risk (<25% I² value), moderate risk (25%–75% I² value), and high risk (>75% I² value). A random-effects model was used if heterogeneity was significant and I² was >50%; otherwise, a fixed-effects model was used.

Funnel plots and Egger's and Begg's tests were performed using the Stata software (version 12.0) to evaluate publication bias. The robustness of the associations was assessed using a sensitivity analysis. In addition, subgroup analyses were conducted and stratified based on population and duration of exposure.

3 Results


3.1 Study selection and characteristics

The study selection process is illustrated in Figure 1. Notably, 526 articles were initially identified using the search terms. After excluding 148 duplicates, the titles and abstracts of 378 articles were screened for eligibility, and the full texts of 59 articles were reviewed. Finally, 16 studies (Del Bo et al., 2013; Riso et al., 2013; Rodriguez-Mateos et al., 2013; Del Bo et al., 2014; McAnulty et al., 2014; Rodriguez-Mateos et al., 2014; Johnson et al., 2015; Stull et al., 2015; Del Bo et al., 2017; Curtis et al., 2019; Rousseau et al., 2021; Curtis et al., 2022; Wang et al., 2022; Woolf et al., 2023b; Wood et al., 2023) were included in the systematic review of the effect of blueberry consumption on endothelial function, of which

TABLE 1 Study characteristics.

Study	Country	Study design	Population	Sample size (T/C)	Health status	Intervention	Control	Duration	Outcomes
Woolf et al. (2023a)	United States	RCT	Postmenopausal women	22/21	Elevated blood pressure or stage1 hypertension	22 g freeze-dried highbush BB powder	22 g placebo powder	12 weeks	FMD, HDL-C, LDL-C SBP, DBP
Wood et al. (2023)	United Kingdom	RCT	Older individuals	27/27	Healthy	26 g freeze-dried BB powder	26 g placebo powder	12 weeks	FMD, HDL-C, LDL-C SBP, DBP
Curtis et al. (2019)	United Kingdom	RCT	Metabolic syndrome	37/39	Patients with metabolic syndrome	13 g freeze-dried BB	Matched placebo	6 months	FMD, HDL-C, LDL-C SBP, DBP
Rodriguez-Mateos et al. (2013)	United Kingdom	RCT	Healthy humans	21/21	Healthy	766 mg total BB polyphenols (equivalent to 240 g fresh BB)	Control drink	1 h	FMD, HDL-C, SBP, DBP
Rodriguez-Mateos et al. (2014)	United Kingdom	RCT	Male volunteers	10/10	Healthy	34 g freeze-dried BB powder (equivalent to 240 g fresh BB)	Control products	0, 1, 2, 4, and 6 h	FMD
Riso et al. (2013)	United States	RCT	Healthy male volunteers	18/18	Healthy	25 g freeze-dried powder	Placebo	6 weeks	RHI, HDL-C. LDL-C, SBP, DBP
Del Bo et al. (2013)	Italy	RCT	Healthy male	10/10	Healthy	300 g of BB	Control jelly	1 h	RHI, SBP, DBP
Del Bo et al. (2014)	Italy	RCT	Young smokers	16/16	Healthy	300 g of BB	Control treatment	2 h	RHI, SBP, DBP
Del Bo et al. (2017)	Italy	RCT	Young volunteers	24/24	12 non-smokers and 12 smokers)	300 g of BB	Control treatment	1 week	RHI, SBP, DBP
Stull et al. (2015)	United States	RCT	Metabolic syndrome	23/21	Adults with metabolic syndrome	45 g of freeze-dried BB powder	Placebo	6 weeks	RHI, SBP, DBP
Curtis et al. (2022)	United Kingdom	RCT	Metabolic syndrome	23/22	Adults with metabolic syndrome	26 g freeze-dried BB powder	Placebo	1h\3h\6h\24h	FMD, HDL-C, DBP

*T, treatment group; C, control group; BB, blueberry; USA, the United States of America; UK, the United Kingdom; RCT, randomize control trail; FMD, Flow-mediated vasodilation; RHI, reactive hyperemia index; SBP, systolic blood pressure; DBP, diastolic blood pressure.



11 (Del Bo et al., 2013; Riso et al., 2013; Rodriguez-Mateos et al., 2013; Del Bo et al., 2014; Rodriguez-Mateos et al., 2014; Stull et al., 2015; Del Bo et al., 2017; Curtis et al., 2019; Curtis et al., 2022; Woolf et al., 2023b; Wood et al., 2023) were incorporated in the meta-analysis (Figure 1).

The characteristics and main findings of the included studies are summarized in Table 1. Of the 16 included studies, seven were conducted in the United Kingdom, six in the United States, and four in Italy. Furthermore, three studies focused on individuals with metabolic syndrome, one focused on postmenopausal women, one included a smoking population, and the remaining studies involved healthy individuals. The duration of blueberry intervention varied between 1 h and 6 months. Moreover, the subjects' demographics and clinical features are outlined in Supplementary Table S1. The risk of bias of 11 included studies was assessed (Supplementary Figure S1) (Table 1).

3.2 Meta-analysis

3.2.1 Effects of blueberry on endothelial function

Five of the six studies that used FMD to assess endothelial function significantly improved, whereas one reported no significant change in endothelial function. The pooled results showed a statistically significant increase of 1.50% for FMD (95% confidence interval (CI): 0.81, 2.20; $I^2 = 87\%$; Figure 2) after blueberry consumption. Subsequently, we assessed the publication bias. The funnel plot exhibited a nearly symmetrical distribution (Supplementary Figure S2); both Egger's test (p = 0.602) and Begg's test (p = 0.707) did not detect publication bias. Moreover, the result of the trim and fill methods also found no trimming performed, and the data remained unchanged when the trim-andfill method was used (Supplementary Table S2). Furthermore, sensitivity analysis was performed to evaluate the resilience of the results (Supplementary Figure S3). The analysis demonstrated that the estimates remained robust even when each study was individually excluded (Figure 2).

When stratifying based on the study population, the results remained statistically significant in the healthy population [mean differences (MD): 2.01, 95% CI: 0.89, 3.12; $I^2 = 88\%$; Figure 3A], patients with metabolic syndrome (MD: 0.62, 95% CI: -0.37, 1.61; $I^2 = 69\%$; Figure 3A) and postmenopausal women with elevated blood pressure or stage 1 hypertension (MD: 1.75, 95% CI: 1.27, 2.23; Figure 3A). The results remained statistically significant in the

acute (hours) and chronic (12 weeks–6 months) studies after stratifying the data based on the duration of blueberry intervention. There was an increase of 1.76 (95% CI: 0.30, 3.22; $I^2 = 90\%$; Figure 3B) and 1.25 (95% CI: 0.72, 1.78; $I^2 = 66\%$; Figure 3B) in short and long-term studies, respectively (Figure 3).

Additionally, we also conducted a subgroup analysis based on the intaking level of anthocyanins. The results showed that the FMD would increase 1.34 (95% CI: 0.20, 2.40; $I^2 = 94\%$; Supplementary Figure S4) when the anthocyanins less that 300 mg, 1.65 (95% CI: 0.94, 2.36; $I^2 = 84\%$; Supplementary Figure S4) with anthocyanins range from 300 to 500, and 2.00 (95% CI: 1.50, 2.40; $I^2 = 0\%$; Supplementary Figure S4) for the dose of over 500 mg.

Five studies used the RHI to test endothelial function; two showed significant improvement in endothelial function, and three showed no significant improvement. The pooled results revealed a notable increase of 0.26 (95% CI: 0.09, 0.42; $I^2 = 72\%$; Figure 4A). Similarly, the funnel plot for the RHI studies exhibited asymmetry (Supplementary Figure S5), with Egger's test (p = 0.002) indicating publication bias, whereas Begg's test (p = 0.462) did not. Furthermore, the trim-and-fill method's results demonstrated the robustness of the estimate because no trimming was performed, and the data remained unchanged (Supplementary Table S3). Sensitivity analysis was conducted to assess the robustness of the results (Supplementary Figure S6). Moreover, upon stratification based on the study population, RHI values were significantly elevated in individuals who smoked or had metabolic syndrome (registering values of 0.32 (95% CI: 0.14, 0.51; $I^2 = 74\%$; Figure 4B), whereas no significant improvement was observed in healthy populations (MD: 0.12; 95% CI: -0.08, 0.33; $I^2 = 0\%$; Figure 4B) (Figure 4).

Additionally, a summary of findings table was built to access the quality of the evidence of the main outcome in this study (Table 2).

3.2.2 Blood pressure and lipid status after blueberry intervention

A meta-analysis of blood pressure was also conducted on the included studies. The pooled results suggested a statistically non-significant decrease of 1.43 mmHg for systolic blood pressure (SBP) (95% CI: -3.11, 0.26; $I^2 = 0\%$; Supplementary Figure S7), but a significant reduction of 1.95 mmHg for diastolic blood pressure (DBP) (95% CI: -3.08, -0.81; $I^2 = 0\%$; Figure 5). When stratified based on the study population, a significant decrease of 3.92 mmHg (95% CI: -6.88, -0.97; $I^2 = 20\%$; Supplementary Figure S8A) and 2.20 mmHg (95% CI: -4.13, -0.27; $I^2 = 11\%$; Supplementary Figure

		leberry			acebo	T - 4 - 1	147-1-1-6	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	otal	Mean	SD	Iotal	weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.11.1 Healthy	0.44	4.40	40	0.04	0.00	40	44 70/	0.05 [4.70, 0.50]	
Rodriguez-Mateos et al. 2014		1.13	10	-0.21		10	14.7%	2.65 [1.72, 3.58]	
Rodriguez-Mateos et al. 2013		0.79	21	-0.17	0.8	21	18.2%	2.51 [2.03, 2.99]	
Vood et al. 2023 Subtotal (95% Cl)	0.86	1.49	32 63	-0.04	1.16	29 60	16.8% 49.7%	0.90 [0.23, 1.57] 2.01 [0.89, 3.12]	
Heterogeneity: Tau² = 0.84; Chi² Test for overall effect: Z = 3.53 (l			P = 0.	.0003);	² = 88	%			
1.11.2 Metabolic syndrome									
Curtis et al. 2019	1.42	1.13	37	0.39	0.99	39	18.2%	1.03 [0.55, 1.51]	
Curtis et al. 2022	-0.2	1.64	23	-0.2	1.86	22	13.9%	0.00 [-1.03, 1.03]	
Subtotal (95% CI)			60			61	32.1%	0.62 [-0.37, 1.61]	
Heterogeneity: Tau² = 0.36; Chi² Fest for overall effect: Z = 1.23 (9 = 0.0	17); l² =	69%				
1.11.3 Postmenopausal wome	n								
Woolf et al. 2023	1.34	0.89	17	-0.41	0.46	15	18.2%	1.75 [1.27, 2.23]	
Subtotal (95% CI)			17			15	18.2%	1.75 [1.27, 2.23]	\bullet
Heterogeneity: Not applicable Test for overall effect: Z = 7.10 (P < 0.00	001)							
									-
Total (95% CI)			140			136	100.0%	1.50 [0.81, 2.20]	
	= 38.06	. df = 5 (140 P < 0.	00001	: l² = 8		100.0%	1.50 [0.81, 2.20]	
Heterogeneity: Tau² = 0.63; Chi² Test for overall effect: Z = 4.25 (P < 0.00	01)	P < 0.			7%	100.0%	1.50 [0.81, 2.20]	-4 -2 0 2 4 Favours [control] Favours [experimental]
Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C	P < 0.00 hi² = 4.6	01) 7, df = 2	P < 0.	0.10), I ²	² = 57.2	7%	100.0%		Favours [control] Favours [experimental]
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Test for subgroup differences: C	P < 0.00 hi ² = 4.6 Blu	01) 7, df = 2 Jeberry	P < 0. (P = (0.10), I ² PI	² = 57.2 acebo	7% ?%		Mean Difference	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Fest for subgroup differences: C Study or Subgroup	P < 0.00 hi² = 4.6	01) 7, df = 2 Jeberry	P < 0. (P = (0.10), I ² PI	² = 57.2 acebo	7% ?%			Favours [control] Favours [experimental]
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Fest for subgroup differences: C Study or Subgroup I.9.1 acute intervention	P < 0.00 hi ² = 4.6 Blu <u>Mean</u>	01) 7, df = 2 Jeberry SD	P < 0. (P = (<u>Fotal</u>	0.10), l ^a Pl <u>Mean</u>	² = 57.2 acebo SD	7% % <u>Total</u>	Weight	Mean Difference IV. Random. 95% CI	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Fest for subgroup differences: C Study or Subgroup .9.1 acute intervention Curtis et al. 2022	P < 0.00 hi ² = 4.6 Blu <u>Mean</u> -0.2	01) 7, df = 2 Jeberry <u>SD</u> 1.64	P < 0. (P = (<u>Fotal</u> 23	0.10), I ² PI <u>Mean</u> -0.2	² = 57.2 acebo SD 1.86	7% % <u>Total</u> 22	Weight 13.9%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup I.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014	P < 0.00 hi ² = 4.6 Blu <u>Mean</u> -0.2 2.44	01) 7, df = 2 Jeberry SD 1.64 1.13	P < 0. (P = 0 Fotal 23 10	0.10), i ² Pl <u>Mean</u> -0.2 -0.21	² = 57.2 acebo SD 1.86 0.98	7% % <u>Total</u> 22 10	<u>Weight</u> 13.9% 14.7%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013	P < 0.00 hi ² = 4.6 Blu <u>Mean</u> -0.2 2.44	01) 7, df = 2 Jeberry <u>SD</u> 1.64	P < 0. (P = (Fotal 23 10 21	0.10), I ² PI <u>Mean</u> -0.2	² = 57.2 acebo SD 1.86	7% % Total 22 10 21	Weight 13.9% 14.7% 18.2%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99]	Favours [control] Favours [experimental] Mean Difference
Heterogeneily: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI)	P < 0.00 hi ² = 4.6 Blu <u>Mean</u> -0.2 2.44 2.34	01) 7, df = 2 sberry 1.64 1.13 0.79	P < 0. (P = 0 <u>Fotal</u> 23 10 21 54	0.10), l ² Pl <u>Mean</u> -0.2 -0.21 -0.17	acebo SD 1.86 0.98 0.8	7% % Total 22 10 21 53	<u>Weight</u> 13.9% 14.7%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58]	Favours [control] Favours [experimental] Mean Difference
Heterogeneily: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ²	P < 0.000 hi ² = 4.6 Blu <u>Mean</u> -0.2 2.44 2.34 = 20.12,	01) 7, df = 2 ieberry SD 1.64 1.13 0.79 df = 2 (P < 0. (P = 0 <u>Fotal</u> 23 10 21 54	0.10), l ² Pl <u>Mean</u> -0.2 -0.21 -0.17	acebo SD 1.86 0.98 0.8	7% % Total 22 10 21 53	Weight 13.9% 14.7% 18.2%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99]	Favours [control] Favours [experimental] Mean Difference
Total (95% CI) Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Test for overall effect: Z = 2.37 (I 1.9.2 chronic intervention	P < 0.000 hi ² = 4.6 Blu <u>Mean</u> -0.2 2.44 2.34 = 20.12,	01) 7, df = 2 ieberry SD 1.64 1.13 0.79 df = 2 (P < 0. (P = 0 <u>Fotal</u> 23 10 21 54	0.10), l ² Pl <u>Mean</u> -0.2 -0.21 -0.17	acebo SD 1.86 0.98 0.8	7% % Total 22 10 21 53	Weight 13.9% 14.7% 18.2%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup I.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Fest for overall effect: Z = 2.37 (I I.9.2 chronic intervention	P < 0.00 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02	01) 7, df = 2 ieberry SD 1.64 1.13 0.79 df = 2 (P < 0. (P = 0 <u>Fotal</u> 23 10 21 54	0.10), I ² PI <u>Mean</u> -0.2 -0.21 -0.17 0001);	acebo SD 1.86 0.98 0.8	7% % Total 22 10 21 53	Weight 13.9% 14.7% 18.2%	Mean Difference <u>IV. Random, 95% CI</u> 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup I.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2014 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Fest for overall effect: Z = 2.37 (I I.9.2 chronic intervention Curtis et al. 2019	P < 0.000 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02; 1.42	01) 7, df = 2 SD 1.64 1.13 0.79 df = 2 (P < 0. (P = (Cotal 23 10 21 54 P < 0.	0.10), I ² PI <u>Mean</u> -0.2 -0.21 -0.17 0001);	² = 57.2 acebo <u>SD</u> 1.86 0.98 0.8 ² = 90' 0.99	7% *% <u>Total</u> 22 10 21 53 %	Weight 13.9% 14.7% 18.2% 46.8%	Mean Difference IV. Random. 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: $Z = 4.25$ (I Fest for subgroup differences: C Study or Subgroup I.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Fest for overall effect: $Z = 2.37$ (I I.9.2 chronic intervention Curtis et al. 2019 Nood et al. 2023 Noolf et al. 2023	P < 0.000 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02 1.42 0.86	01) 7, df = 2 sp 1 1.64 1.13 0.79 df = 2 ()	P < 0. (P = ([Otal] 23 10 21 54 P < 0. 37 32 17	0.10), I ² PI <u>Mean</u> -0.2 -0.21 -0.17 0001); 0.39	² = 57.2 acebo <u>SD</u> 1.86 0.98 0.8 ² = 90' 0.99 1.16	7% *% Total 22 10 21 53 % 39 29 15	Weight 13.9% 14.7% 18.2% 46.8% 18.2% 16.8% 18.2%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57] 1.75 [1.27, 2.23]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Fest for overall effect: Z = 4.25 (I Fest for subgroup differences: C Study or Subgroup .9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Fest for overall effect: Z = 2.37 (I .9.2 chronic intervention Curtis et al. 2019 Vood et al. 2023 Voolf et al. 2023 Subtotal (95% CI)	P < 0.000 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02 1.42 0.86 1.34	01) 7, df = 2 SD 1.64 1.13 0.79 df = 2 () 1.13 1.49 0.89	P < 0. (P = (23 10 21 54 P < 0. 37 32 17 86	0.10), I ² PI Mean -0.2 -0.21 -0.17 00001); 0.39 -0.04 -0.41	acebo SD 1.86 0.98 0.8 ² = 90 0.99 1.16 0.46	7% Total 22 10 21 53 % 39 29	Weight 13.9% 14.7% 18.2% 46.8%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Test for overall effect: Z = 2.37 (I 1.9.2 chronic intervention Curtis et al. 2019 Nood et al. 2023 Noolf et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.15; Chi ²	P < 0.000 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02 1.42 0.86 1.34 = 5.93, 6	01) 7, df = 2 Beberry 5D 1 1.64 1.13 0.79 df = 2 () 1.13 1.49 0.89 df = 2 (P	P < 0. (P = (23 10 21 54 P < 0. 37 32 17 86	0.10), I ² PI Mean -0.2 -0.21 -0.17 00001); 0.39 -0.04 -0.41	acebo SD 1.86 0.98 0.8 ² = 90 0.99 1.16 0.46	7% *% Total 22 10 21 53 % 39 29 15	Weight 13.9% 14.7% 18.2% 46.8% 18.2% 16.8% 18.2%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57] 1.75 [1.27, 2.23]	Favours [control] Favours [experimental] Mean Difference
Heterogeneily: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneily: Tau ² = 1.48; Chi ² Test for overall effect: Z = 2.37 (I	P < 0.000 hi ² = 4.6 Mean -0.2 2.44 2.34 = 20.12, P = 0.02 1.42 0.86 1.34 = 5.93, 6	01) 7, df = 2 Beberry 5D 1 1.64 1.13 0.79 df = 2 () 1.13 1.49 0.89 df = 2 (P	P < 0. (P = (23 10 21 54 P < 0. 37 32 17 86	0.10), I ² PI Mean -0.2 -0.21 -0.17 00001); 0.39 -0.04 -0.41	acebo SD 1.86 0.98 0.8 ² = 90 0.99 1.16 0.46	7% *** Total 22 10 21 53 *** 39 29 15 83	Weight 13.9% 14.7% 18.2% 46.8% 18.2% 16.8% 18.2%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57] 1.75 [1.27, 2.23]	Favours [control] Favours [experimental] Mean Difference
Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Test for overall effect: Z = 2.37 (I 1.9.2 chronic intervention Curtis et al. 2019 Wood et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.15; Chi ² Test for overall effect: Z = 4.60 (I	$P < 0.000$ $hi^{2} = 4.6^{\circ}$ Blu <u>Mean</u> -0.2 2.44 2.34 = 20.12, P = 0.02, 1.42 0.86 1.34 = 5.93, 0 P < 0.000	01) 7, df = 2 SD 1.64 1.13 0.79 df = 2 () 1.13 1.49 0.89 df = 2 (P 001)	P < 0. ($P = 0$ ($P = 0$ 23 10 21 54 P < 0. 37 32 17 86 $^{\circ} = 0.0$ 140	-0.2 -0.21 -0.21 -0.21 -0.17 0001); -0.04 -0.04 -0.41 -5); l ² =	acebo <u>SD</u> 1.86 0.98 0.8 ² = 90 0.99 1.16 0.46	7% ************************************	Weight 13.9% 14.7% 18.2% 46.8% 18.2% 18.2% 53.2%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57] 1.75 [1.27, 2.23] 1.25 [0.72, 1.78]	Favours [control] Favours [experimental]
Heterogeneity: Tau ² = 0.63; Chi ² Test for overall effect: Z = 4.25 (I Test for subgroup differences: C Study or Subgroup 1.9.1 acute intervention Curtis et al. 2022 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2014 Rodriguez-Mateos et al. 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 1.48; Chi ² Test for overall effect: Z = 2.37 (I 1.9.2 chronic intervention Curtis et al. 2019 Wood et al. 2023 Woolf et al. 2023 Woolf et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.15; Chi ² Test for overall effect: Z = 4.60 (I Total (95% CI)	$P < 0.000$ $hi^{2} = 4.6^{\circ}$ Blu Mean -0.2 2.44 2.34 = 20.12, P = 0.02; 1.42 0.86 1.34 = 5.93, (P < 0.000 = 38.06,	01) 7, df = 2 Beberry SD 1.64 1.13 0.79 df = 2 (0 1.13 1.49 0.89 df = 2 (P 001) df = 5 (P < 0. ($P = 0$ ($P = 0$ 23 10 21 54 P < 0. 37 32 17 86 $^{\circ} = 0.0$ 140	-0.2 -0.21 -0.21 -0.21 -0.17 0001); -0.04 -0.04 -0.41 -5); l ² =	acebo <u>SD</u> 1.86 0.98 0.8 ² = 90 0.99 1.16 0.46	7% ************************************	Weight 13.9% 14.7% 18.2% 46.8% 18.2% 18.2% 53.2%	Mean Difference IV. Random, 95% CI 0.00 [-1.03, 1.03] 2.65 [1.72, 3.58] 2.51 [2.03, 2.99] 1.76 [0.30, 3.22] 1.76 [0.30, 3.22] 1.03 [0.55, 1.51] 0.90 [0.23, 1.57] 1.75 [1.27, 2.23] 1.25 [0.72, 1.78]	Favours [control] Favours [experimental] Mean Difference

Forest plot of meta-analysis of flow-mediated vasodilation (FMD) for population based on health status (A) and intervention duration (B).

S7B) in smoking population for SBP and DBP, respectively. No significant changes were observed in SBP and DBP across the other populations (Supplementary Figure S8) (Figure 5).

The meta-analysis of lipid status yielded non-significant result of -0.02 (95% CI: -0.09, 0.04; I² = 0%; Supplementary Figure S9) for LDL-C. Notably, a significant result of 0.07 (95% CI: 0.04, 0.10; I² = 28%; Supplementary Figure S10) for HDL-C was initially reported, and the P for subgroup analysis (healthy, metabolic syndrome and postmenopausal women) was 0.05.

4 Discussion

The current systematic review and meta-analysis revealed significant improvements in endothelial function following

blueberry intervention in adults. This improvement was based on data from 11 studies, including 400 participants. Significant increases of 1.50% (95% CI: 0.81, 2.20) and 0.26 (95% CI: 0.09, 0.42) were observed in FMD and RHI, respectively, following blueberry supplementation. Furthermore, this analysis revealed a significant decrease of 1.95 mmHg (95% CI: -3.08, -0.81) in diastolic blood pressure; and subgroups analysis found that both systolic and diastolic blood pressure were significantly decreased in smoking population. However, no significant results were observed in pooled results of systolic blood pressure or lipid status following blueberry supplementation.

The present study is consistent with a previous investigation (Fairlie-Jones et al., 2017), which demonstrated significant improvements in endothelial function, as assessed by FMD, including subgroup analyses for acute and chronic use. However,

	B	lueberry		F	lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Del Bo et al. 2014	-0.15	0.13	16	-0.39	0.36	16	21.8%	0.24 [0.05, 0.43]	
Del Bo et al. 2013	-0.01	0.354	10	-0.12	0.26	10	16.7%	0.11 [-0.16, 0.38]	
Del Bo et al. 2017	0.65	0.3771	24	0.45	0.4657	24	18.6%	0.20 [-0.04, 0.44]	
Riso et al. 2013	0.03	0.501	18	-0.11	0.449	18	14.7%	0.14 [-0.17, 0.45]	
Stull et al. 2015	0.23	0.105	23	-0.23	0.155	21	28.2%	0.46 [0.38, 0.54]	
Total (95% CI)			91			89	100.0%	0.26 [0.09, 0.42]	
Heterogeneity: Tau ² =	0.02; Ch	ni² = 14.3	2, df =	4 (P = C	.006); l ²	= 72%		-	-0.5 -0.25 0 0.25 0.5
Test for overall effect:	Z = 3.04	(P = 0.0)	02)						
									Favours [control] Favours [experimental]
3									
	BI	lueberry		P	lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.10.1 healthy popula	tion								
Del Bo et al. 2013	-0.01	0.354	10	-0.12	0.26	10	16.7%	0.11 [-0.16, 0.38]	
Riso et al. 2013	0.03	0.501	18	-0.11	0.449	18	14.7%	0.14 [-0.17, 0.45]	
Subtotal (95% CI)			28			28	31.4%	0.12 [-0.08, 0.33]	
Heterogeneity: Tau ² =	0.00; Ch	i ² = 0.02	, df = 1	(P = 0.8)	39); l² = ()%			
Test for overall effect: 2	Z = 1.18	(P = 0.24	4)						
	ulation								
1.10.2 unhealthy pop	ulation -0.15	0.13	16	-0.39	0.36	16	21.8%	0.24 [0.05, 0.43]	
1.10.2 unhealthy pop Del Bo et al. 2014	-0.15	0.13 0.3771	16 24		0.36 0.4657	16 24	21.8% 18.6%	0.24 [0.05, 0.43] 0.20 [-0.04, 0.44]	
1.10.2 unhealthy pop Del Bo et al. 2014 Del Bo et al. 2017	-0.15		24 23						
1.10.2 unhealthy pop Del Bo et al. 2014 Del Bo et al. 2017 Stull et al. 2015	-0.15 0.65	0.3771	24	0.45	0.4657	24	18.6%	0.20 [-0.04, 0.44]	
1.10.2 unhealthy pop Del Bo et al. 2014 Del Bo et al. 2017 Stull et al. 2015 Subtotal (95% CI)	-0.15 0.65 0.23	0.3771 0.105	24 23 63	0.45 -0.23	0.4657 0.155	24 21 61	18.6% 28.2%	0.20 [-0.04, 0.44] 0.46 [0.38, 0.54]	
1.10.2 unhealthy pop Del Bo et al. 2014 Del Bo et al. 2017 Stull et al. 2015 Subtotal (95% CI) Heterogeneity: Tau ² =	-0.15 0.65 0.23 0.02; Ch	0.3771 0.105 hi ² = 7.64	24 23 63 , df = 2	0.45 -0.23	0.4657 0.155	24 21 61	18.6% 28.2%	0.20 [-0.04, 0.44] 0.46 [0.38, 0.54]	
1.10.2 unhealthy pop Del Bo et al. 2014 Del Bo et al. 2017 Stull et al. 2015 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2 Total (95% Cl)	-0.15 0.65 0.23 0.02; Ch	0.3771 0.105 hi ² = 7.64	24 23 63 , df = 2	0.45 -0.23	0.4657 0.155	24 21 61 74%	18.6% 28.2%	0.20 [-0.04, 0.44] 0.46 [0.38, 0.54]	
1.10.2 unhealthy population of the set of th	-0.15 0.65 0.23 0.02; Ch Z = 3.42	0.3771 0.105 hi ² = 7.64 (P = 0.00	24 23 63 , df = 2 006) 91	0.45 -0.23 (P = 0.0	0.4657 0.155 02); I ² = 7	24 21 61 74% 89	18.6% 28.2% 68.6%	0.20 [-0.04, 0.44] 0.46 [0.38, 0.54] 0.32 [0.14, 0.51]	
1.10.2 unhealthy population of the set of th	-0.15 0.65 0.23 0.02; Ch Z = 3.42 0.02; Ch	0.3771 0.105 $hi^2 = 7.64$ (P = 0.00) $hi^2 = 14.32$	24 23 63 , df = 2 006) 91 2, df = 4	0.45 -0.23 (P = 0.0	0.4657 0.155 02); I ² = 7	24 21 61 74% 89	18.6% 28.2% 68.6%	0.20 [-0.04, 0.44] 0.46 [0.38, 0.54] 0.32 [0.14, 0.51]	-0.5 -0.25 0 0.25 0.5 Favours [control] Favours [experimental]

TABLE 2 Summary of findings of main outcome.

Outcomes	Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
FDM (%)	1.50 (0.81, 2.20)	276 (6)	⊕⊕⊕⊝ ^a moderate
RHI	0.32 (0.14, 0.51)	124 (5)	⊕⊕⊕⊝ ^a moderate
ΔSBP	-1.43 (-3.11, 0.26)	400 (10)	⊕⊕⊕⊝ ^b moderate
ΔDBP	-1.95 (-3.08, -0.81)	400 (10)	⊕⊕⊕⊖ ^b moderate

GRADE, working group grades of evidence.

consumption.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

^aDowngraded once for serious inconsistence.

^bDowngraded once for serious imprecision due to wide confidence intervals.

an improvement was only detected through FMD in a previous study, with no significant enhancement observed in RHI assay results. In contrast, in addition to FMD, this study demonstrated a significant improvement in endothelial function, as indicated by RHI.

In addition, this study's subgroup analysis was consistent with another similar study (Kay et al., 2012), showing that acute intervention was more effective than chronic intervention in increasing the response effect of FMD. This divergence between this study and others lies in the intervention; previous studies used anthocyanin-rich or flavonoid-rich foods/extracts, whereas the present study used blueberries. However, increased FMD values were more pronounced in the healthy population than in the unhealthy population. Conversely, RHI alteration values were higher in the non-healthy population than in the healthy population.

Furthermore, supplementation with these fruits showed no significant effect on blood pressure in another study examining the impact of blueberries or cranberries on blood pressure (Delpino

	BI	ueberry	,	Р	lacebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Curtis et al. 2019	-0.75	5.61	37	1.1	5.54	39	20.5%	-1.85 [-4.36, 0.66]	
Curtis et al. 2022	-8.2	4.922	22	-5.8	4.7	22	15.9%	-2.40 [-5.24, 0.44]	
el Bo et al. 2014	11.15	2.88	16	13.63	2.88	16	32.3%	-2.48 [-4.48, -0.48]	
Del Bo et al. 2013	-2.6	6.15	10	0	8.93	10	2.9%	-2.60 [-9.32, 4.12]	
Del Bo et al. 2017	4.09	10.56	12	2.35	8.11	12	2.3%	1.74 [-5.79, 9.27]	
Riso et al. 2013	-0.2	8.12	18	0.5	8.35	18	4.4%	-0.70 [-6.08, 4.68]	
Rodriguez-Mateos et al. 2013	-1	8.37	10	1	12.64	10	1.5%	-2.00 [-11.40, 7.40]	· · · · · · · · · · · · · · · · · · ·
Stull et al. 2015	-5.5	9.59	23	-7.3	8.15	21	4.7%	1.80 [-3.45, 7.05]	
Wood et al. 2023	-1.28	7.83	32	1.4	7.19	29	9.1%	-2.68 [-6.45, 1.09]	
Voolf et al. 2023	-1	4.69	22	1	9.38	21	6.5%	-2.00 [-6.46, 2.46]	
Fotal (95% CI)			202			198	100.0%	-1.95 [-3.08, -0.81]	◆
Heterogeneity: Chi ² = 3.65, df =	9 (P = 0	.93); l² =	= 0%						-10 -5 0 5 10
est for overall effect: Z = 3.36 (P = 0.00	08)							Favours [experimental] Favours [control]
GURE 5									
prest plot of meta-analysis of	of diaste	lic blo	od pre	SCUIPA		for all	subjects	after blueberny cons	sumption

et al., 2023), which is partially consistent with our research findings. We also found a non-significant result in systolic blood pressure, but the diastolic blood pressure was significantly decreased. Additionally, in subgroups analysis, both systolic and diastolic blood pressure were significantly decreased in smoking population after blueberry consumption. This may implicate that blueberry intervention could be a useful dietary intervention to control blood pressure in smoking population.

In addition, a study examining the impact of blueberry intake on the clinical features of metabolic syndrome, significant improvements in blood pressure, plasma oxidized LDL, and lipid peroxidation were observed in patients with metabolic syndrome (Basu et al., 2010). Moreover, a meta-analysis (Huang et al., 2016) investigating the impact of berry consumption on cardiovascular risk suggested a statistically significant reduction in LDL-C levels. However, in our study, after conducting a meta-analysis of HDL-C and LDL-C levels based on the included articles, the pooled results showed no statistically significant effect of blueberry intake on both serum concentrations. This could be because of the selective inclusion of studies based on endothelial function or differences in blueberry consumption.

Epidemiological studies have proposed that consuming polyphenol-rich foods may reduce the risk of cardiovascular diseases (CVD) by enhancing the production and bioavailability of NO, thus improving endothelial function and vascular tone (Naissides et al., 2006). The results of an animal experiment suggested that blueberry consumption could prevent, delay, or lessen the severity of endothelial dysfunction, and the mechanism was thought to be blueberry metabolites inhibiting NOX-mediated ROS production and increasing bioavailable NO (Bharat et al., 2018). In addition, a clinical trial suggested that increased plasma polyphenol metabolites after blueberry consumption may enhance NO bioactivity and improve lipid status (Curtis et al., 2019). However, because the polyphenol metabolites in blueberries are numerous and unspecific, it is difficult to determine their exact source and the main metabolite that act primarily (Woolf et al., 2023a).

Besides, another study found that obese Zucker rats consume blueberries seems to reduce inflammation in the perivascular adipose tissue, potentially affecting overall vascular inflammation and endothelial function (Vendrame et al., 2016). Overall, current studies suggests that increasing responsiveness to NO, the antiinflammation and anti-oxidative stress (Riso et al., 2013) are the main mechanisms by which blueberries exert vascular endothelial protective effects. Several animal researches concluded that blueberry mainly functioned through the eNOS/NO pathway, COX pathway (Klimis-Zacas et al., 2016), NO-sGC-cGMP signaling pathway (Kristo et al., 2013) and reducing NOX4 activity (Petersen et al., 2022).

Furthermore, the study found a dose-dependent relationship between improved endothelial function and blueberry intake. In the sub-analysis of anthocyanins, the mean difference of FMD was increased with the increased level of anthocyanins. In addition, blueberry polyphenols increased with increased enhancement of endothelial function, reaching a peak at 766 mg (equivalent to 240 fresh blueberries) (Rodriguez-Mateos et al., 2013). However, the endpoint was evaluated only 1 h after ingestion, and long-term study results are unavailable.

Among the included studies, two types of blueberry supplements were administered: fresh blueberry drinks and freeze-dried blueberry powder. Regardless of the blueberry type, researchers hypothesized that polyphenols, often categorized as flavonoids (such as anthocyanins, flavonols, and phenolic acids) and non-flavonoids (Di Lorenzo et al., 2021), play a central role. Short-term studies have indicated a correlation between increased polyphenol metabolites (ferulic, isoferulic, benzoic, vanillic, salicylic, and caffeic acids) in serum or urine after blueberry consumption and the short-term improvement in vascular function observed at 1, 2, and 6-h post-consumption (Rodriguez-Mateos et al., 2013; Rodriguez-Mateos et al., 2014). These findings suggest that the polyphenols in blueberries enhance various functions, including vascular functions. However, polyphenols are absorbed and metabolized relatively quickly in the human body.

In addition, according to the FMD testing guidelines (Corretti et al., 2002), given the numerous factors influencing vascular reactivity, including smoking, diet, drugs, and sympathetic nerve stimulation, FMD assessment typically necessitates 8–12 h of fasting. It should be conducted in a quiet, temperature-controlled room. Another study's (Riso et al., 2013) results revealed no anthocyanin detection in the serum and no significant improvement in vascular function 12 h after blueberry

consumption. However, in most of the included studies, FMD testing followed established guidelines, such as participants in a supine position at room temperature with dimmed lighting and a fasting state.

This study has some limitations. First, the funnel plots for both FMD and RHI exhibited asymmetry, and Egger's test suggested a potential publication bias. However, this review's limited number of published papers presented a challenge for conducting a thorough assessment of publication bias. Notably, most of the articles we incorporated had small sample sizes, featuring heterogeneity regarding blueberry dose and type, duration, and population characteristics, all of which constrain the robustness of our findings and necessitate its cautious interpretation. Besides, due to 5s limited research, the detailed mechanisms of blueberry on endothelial function in human remains unclear. Future studies were required in the future. In this study, a random effects model was used to mitigate the impact of heterogeneity on the estimated effect sizes. Finally, various techniques were used to assess endothelial function, each with different levels of accuracy.

5 Conclusion

Our meta-analysis showed that blueberry consumption can significantly improve endothelial function, as evaluated using FMD and RHI. Significant improvement in diastolic blood pressure was observed. Furthermore, according to subgroup analysis, a significant decrease in blood pressure was observed in the smoking population. However, there were no significant results except for a subgroup analysis that found increased HDL-C in healthy population after blueberry consumption. Large-sample randomized controlled trials based on sub-populations are required to verify these effects on vascular function. In addition, further investigations are warranted to explore the mechanisms underlying the effect of blueberries on endothelial function.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

References

Axtell, A. L., Gomari, F. A., and Cooke, J. P. (2010). Assessing endothelial vasodilator function with the Endo-PAT 2000. J. Vis. Exp., 2167. doi:10.3791/2167

Basu, A., Du, M., Leyva, M. J., Sanchez, K., Betts, N. M., Wu, M., et al. (2010). Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. *J. Nutr.* 140, 1582–1587. doi:10.3945/jn.110.124701

Bharat, D., Cavalcanti, R. R. M., Petersen, C., Begaye, N., Cutler, B. R., Costa, M. M. A., et al. (2018). Blueberry metabolites attenuate lipotoxicity-induced endothelial dysfunction. *Mol. Nutr. food Res.* 62. doi:10.1002/mnfr.201700601

Bove, M., Cicero, A. F. G., and Borghi, C. (2017). The effect of xanthine oxidase inhibitors on blood pressure and renal function. *Curr. Hypertens. Rep.* 19, 95. doi:10. 1007/s11906-017-0793-3

Celermajer, D. S. (1997). Endothelial dysfunction: does it matter? Is it reversible? J. Am. Coll. Cardiol. 30, 325-333. doi:10.1016/s0735-1097(97)00189-7

Author contributions

BD: Writing-review and editing, Writing-original draft, Software, Data curation, Conceptualization. YL: Writing-review and editing, Writing-original draft, Software, Formal Analysis. RZ: Writing-original draft, Methodology, Formal Analysis. TR: Writing-review and editing. WL: Writing-review and editing, Resources, Project administration. JY: Writing-review and editing, Validation, Supervision. YY: Writing-review and editing, Software, Methodology. DM: Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Key R&D Program of China (2021YFC2701700, 2021YFC2701704); National Natural Science Foundation of China (81971433, 81971428, 82271749, 82201905,82371717); the Fundamental Research Funds for the Central University (SCU2023D006).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2024.1368892/ full#supplementary-material

Corretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., Creager, M. A., et al. (2002). Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39, 257–265. doi:10.1016/s0735-1097(01)01746-6

Curtis, P. J., Berends, L., Van Der Velpen, V., Jennings, A., Haag, L., Chandra, P., et al. (2022). Blueberry anthocyanin intake attenuates the postprandial cardiometabolic effect of an energy-dense food challenge: results from a double blind, randomized controlled trial in metabolic syndrome participants. *Clin. Nutr.* 41, 165–176. doi:10.1016/j.clnu.2021.11.030

Curtis, P. J., Van Der Velpen, V., Berends, L., Jennings, A., Feelisch, M., Umpleby, A. M., et al. (2019). Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial. *Am. J. Clin. Nutr.* 109, 1535–1545. doi:10.1093/ajcn/ nqy380

Cutler, B. R., Petersen, C., and Anandh Babu, P. V. (2017). Mechanistic insights into the vascular effects of blueberries: evidence from recent studies. *Mol. Nutr. Food Res.* 61. doi:10.1002/mnfr.201600271

Del Bo, C., Deon, V., Campolo, J., Lanti, C., Parolini, M., Porrini, M., et al. (2017). A serving of blueberry (V. corymbosum) acutely improves peripheral arterial dysfunction in young smokers and non-smokers: two randomized, controlled, crossover pilot studies. *Food Funct.* 8, 4108–4117. doi:10.1039/c7fo00861a

Del Bo, C., Porrini, M., Fracassetti, D., Campolo, J., Klimis-Zacas, D., and Riso, P. (2014). A single serving of blueberry (V. corymbosum) modulates peripheral arterial dysfunction induced by acute cigarette smoking in young volunteers: a randomized-controlled trial. *Food Funct.* 5, 3107–3116. doi:10.1039/c4fo00570h

Del Bo, C., Riso, P., Campolo, J., Moller, P., Loft, S., Klimis-Zacas, D., et al. (2013). A single portion of blueberry (Vaccinium corymbosum L) improves protection against DNA damage but not vascular function in healthy male volunteers. *Nutr. Res.* 33 (3), 220–227. doi:10.1016/j.nutres.2012.12.009

Delpino, F. M., Dos Santos, F. S., Flores, T. R., Cerqueira, H. S., and Santos, H. O. (2023). The effects of blueberry and cranberry supplementation on blood pressure in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized clinical trials. *Phytotherapy Res.* 38, 646–661. doi:10.1002/ptr.8069

Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P., Tognolini, M., Borges, G., and Crozier, A. (2013). Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. *Antioxid. Redox Signal* 18, 1818–1892. doi:10.1089/ars.2012.4581

Di Lorenzo, C., Colombo, F., Biella, S., Stockley, C., Restani, P., Egeo, G., et al. (2021). Applications of ketogenic diets in patients with headache: clinical recommendations. *Nutrients* 13, 2307. doi:10.3390/nu13072307

Durand, M. J., and Gutterman, D. D. (2013). Diversity in mechanisms of endothelium-dependent vasodilation in health and disease. *Microcirculation* 20, 239–247. doi:10.1111/micc.12040

Fairlie-Jones, L., Davison, K., Fromentin, E., and Hill, A. M. (2017). The effect of anthocyanin-rich foods or extracts on vascular function in adults: a systematic review and meta-analysis of randomised controlled trials. *Nutrients* 9 (8), 908. (no pagination). doi:10.3390/nu9080908

Huang, H., Chen, G., Liao, D., Zhu, Y., and Xue, X. (2016). Effects of berries consumption on cardiovascular risk factors: a meta-analysis with trial sequential analysis of randomized controlled trials. *Sci. Rep.* 6, 23625. doi:10.1038/srep23625

Johnson, S. A., Figueroa, A., Navaei, N., Wong, A., Kalfon, R., Ormsbee, L. T., et al. (2015). Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, doubleblind, placebo-controlled clinical trial. *J. Acad. Nutr. Dietetics* 115, 369–377. doi:10. 1016/j.jand.2014.11.001

Kay, C. D., Hooper, L., Kroon, P. A., Rimm, E. B., and Cassidy, A. (2012). Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. *Mol. Nutr. Food Res.* 56, 1605–1616. doi:10.1002/mnfr.201200363

Kinugawa, S., Post, H., Kaminski, P. M., Zhang, X., Xu, X., Huang, H., et al. (2003). Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes: the role of angiotensin II type 1 receptor and NAD(P)H oxidase. *Circulation* 108, 2934–2940. doi:10.1161/01.CIR. 000096488.78151.97

Klimis-Zacas, D., Vendrame, S., and Kristo, A. S. (2016). Wild blueberries attenuate risk factors of the metabolic syndrome. J. Berry Res. 6, 225–236. doi:10.3233/jbr-160136

Kristo, A. S., Kalea, A. Z., Schuschke, D. A., and Klimis-Zacas, D. (2013). Attenuation of alpha-adrenergic-induced vasoconstriction by dietary wild blueberries (Vaccinium angustifolium) is mediated by the NO-cGMP pathway in spontaneously hypertensive rats (SHRs). *Int. J. Food Sci. Nutr.* 64, 979–987. doi:10.3109/09637486.2013.825698

Mcanulty, L. S., Collier, S. R., Landram, M. J., Whittaker, D. S., Isaacs, S. E., Klemka, J. M., et al. (2014). Six weeks daily ingestion of whole blueberry powder increases natural killer cell counts and reduces arterial Stiffness in sedentary males and females. *Nutr. Res.* 34, 577–584. doi:10.1016/j.nutres.2014.07.002

Naissides, M., Mamo, J. C., James, A. P., and Pal, S. (2006). The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. *Atherosclerosis* 185, 438–445. doi:10.1016/j.atherosclerosis.2005.06.027

Parenti, A., Pala, L., Paccosi, S., and Rotella, C. M. (2017). Potential role for dendritic cells in endothelial dysfunction, diabetes and cardiovascular disease. *Curr. Pharm. Des.* 23, 1435–1444. doi:10.2174/1381612823666170124125826

Petersen, C., Bharat, D., Wankhade, U. D., Kim, J. S., Cutler, B. R., Denetso, C., et al. (2022). Dietary blueberry ameliorates vascular complications in diabetic mice possibly through NOX4 and modulates composition and functional diversity of gut microbes. *Mol. Nutr. Food Res.* 66, e2100784. doi:10.1002/mnfr.202100784

Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., Sethi, G., et al. (2013). The vascular endothelium and human diseases. *Int. J. Biol. Sci.* 9, 1057–1069. doi:10.7150/ijbs.7502

Riso, P., Klimis-Zacas, D., Del Bo, C., Martini, D., Campolo, J., Vendrame, S., et al. (2013). Effect of a wild blueberry (Vaccinium angustifolium) drink intervention on markers of oxidative stress, inflammation and endothelial function in humans with cardiovascular risk factors. *Eur. J. Nutr.* 52 (3), 949–961. doi:10.1007/s00394-012-0402-9

Rodriguez-Mateos, A., George, T., Heiss, C., and Spencer, J. (2014). Impact of processing on the bioavailability and vascular effects of blueberry (poly)phenols. *FASEB J. Conf. Exp. Biol.* 28. doi:10.1096/fasebj.28.1_supplement.831.12

Rodriguez-Mateos, A., Rendeiro, C., Bergillos-Meca, T., Tabatabaee, S., George, T. W., Heiss, C., et al. (2013). Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. *Am. J. Clin. Nutr.* 98 (5), 1179–1191. doi:10.3945/ajcn.113.066639

Rousseau, M., Horne, J., Guenard, F., De Toro-Martin, J., Garneau, V., Guay, V., et al. (2021). An 8-week freeze-dried blueberry supplement impacts immune-related pathways: a randomized, double-blind placebo-controlled trial. *Genes Nutr.* 16, 7. doi:10.1186/s12263-021-00688-2

Silva, B. R., Pernomian, L., and Bendhack, L. M. (2012). Contribution of oxidative stress to endothelial dysfunction in hypertension. *Front. Physiol.* 3, 441. doi:10.3389/fphys.2012.00441

Stote, K. S., Sweeney, M. I., Kean, T., Baer, D. J., Novotny, J. A., Shakerley, N. L., et al. (2017). The effects of 100% wild blueberry (Vaccinium angustifolium) juice consumption on cardiometablic biomarkers: a randomized, placebo-controlled, crossover trial in adults with increased risk for type 2 diabetes. *BMC Nutr.* 3, 45. doi:10.1186/s40795-017-0164-0

Stull, A. J., Cash, K. C., Champagne, C. M., Gupta, A. K., Boston, R., Beyl, R. A., et al. (2015). Blueberries improve endothelial function, but not blood pressure, in adults with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients* 7, 4107–4123. doi:10.3390/nu7064107

Vendrame, S., Tsakiroglou, P., Kristo, A. S., Schuschke, D. A., and Klimis-Zacas, D. (2016). Wild blueberry consumption attenuates local inflammation in the perivascular adipose tissue of obese Zucker rats. *Appl. Physiol. Nutr. Metab.* 41, 1045–1051. doi:10. 1139/apnm-2016-0160

Virdis, A., and Taddei, S. (2011). How to evaluate microvascular organ damage in hypertension: assessment of endothelial function. *High. Blood Press Cardiovasc Prev.* 18, 163–167. doi:10.2165/11593630-00000000-00000

Virmani, R., Burke, A. P., Kolodgie, F. D., and Farb, A. (2002). Vulnerable plaque: the pathology of unstable coronary lesions. *J. Interv. Cardiol.* 15, 439–446. doi:10.1111/j. 1540-8183.2002.tb01087.x

Wang, Y., Gallegos, J. L., Haskell-Ramsay, C., and Lodge, J. K. (2022). Effects of blueberry consumption on cardiovascular health in healthy adults: a cross-over randomised controlled trial. *Nutrients* 14, 2562. doi:10.3390/nu14132562

Wood, E., Hein, S., Mesnage, R., Fernandes, F., Abhayaratne, N., Xu, Y., et al. (2023). Wild blueberry (Poly)phenols can improve vascular function and cognitive performance in healthy older males and females: a double-blind randomized controlled trial. *Am. J. Clin. Nutr.* 117, 1306–1319. doi:10.1016/j.ajcnut.2023.03.017

Woolf, E. K., Lee, S. Y., Ghanem, N., Vazquez, A. R., and Johnson, S. A. (2023a). Protective effects of blueberries on vascular function: a narrative review of preclinical and clinical evidence. *Nutr. Res.* 120, 20–57. doi:10.1016/j.nutres.2023.09.007

Woolf, E. K., Terwoord, J. D., Litwin, N. S., Vazquez, A. R., Lee, S. Y., Ghanem, N., et al. (2023b). Daily blueberry consumption for 12 weeks improves endothelial function in postmenopausal women with above-normal blood pressure through reductions in oxidative stress: a randomized controlled trial. *Food & Funct.* 14, 2621–2641. doi:10.1039/d3fo00157a